Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MGLL | Q99685 | 5/20 | 0.58 |
| ▸ | FAAH | O00519 | 2/20 | 0.53 |
| ▸ | GPX4 | P36969 | 5/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.46 |
| ▸ | TACR3 | P29371 | 1/20 | 0.44 |
| ▸ | CACNA2D1 | P54289 | 5/20 | 0.44 |
| ▸ | CACNB1 | Q02641 | 5/20 | 0.44 |
| ▸ | CACNA1B | Q00975 | 4/20 | 0.44 |
| ▸ | CACNA1C | Q13936 | 3/20 | 0.44 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.44 |
| ▸ | CACNA1A | O00555 | 1/20 | 0.43 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL916798 | 0.93 | MGLL (0.55) | MGLLFAAHGPX4CYP3A4CYP3A5 | |
| SCHEMBL917124 | 0.92 | MGLL (0.69) | MGLLFAAHTACR3CACNA2D1CACNB1 | |
| SCHEMBL916475 | 0.84 | MGLL (0.81) | MGLLFAAHGPX4CYP3A4CYP3A5 | |
| SCHEMBL3016226 | 0.77 | HPGD (0.42) | MGLLFAAH | |
| SCHEMBL917630 | 0.74 | MGLL (1.00) | MGLLFAAHCACNA2D1CACNB1CACNA1B | |
| SCHEMBL916928 | 0.73 | MGLL (0.81) | MGLLFAAHCACNA2D1CACNB1CACNA1B | |
| SCHEMBL31023838 | 0.70 | MGLL (0.60) | MGLLFAAHGPX4 | |
| SCHEMBL17276651 | 0.70 | GPX4 (0.56) | MGLLFAAHGPX4CYP3A4CYP3A5 | |
| SCHEMBL917195 | 0.69 | GPX4 (0.69) | MGLLGPX4TACR3CACNA2D1CACNB1 | |
| SCHEMBL31023805 | 0.69 | MGLL (0.48) | MGLLFAAHGPX4TACR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035893-A1 | TRIAZOLOPYRIDINE CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-02-11 | — | — | US | claimed |
| US-20110071161-A1 | TRIAZOLOPYRIDINE CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-03-24 | — | — | US | disclosed |
| US-7868007-B2 | Triazolopyridine carboxamide derivatives, preparation thereof and therapeutic use thereof | SANOFI-AVENTIS (FR) | 2011-01-11 | — | — | US | disclosed |
| EP-2146991-B1 | TRIAZOLOPYRIDINE CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI AVENTIS (FR) | 2010-07-28 | — | — | EP | disclosed |
| US-20100035893-A1 | TRIAZOLOPYRIDINE CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-02-11 | — | — | US | disclosed |
| EP-2146991-A2 | TRIAZOLOPYRIDINE CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2010-01-27 | — | — | EP | disclosed |
| WO-2008145842-A2 | TRIAZOLOPYRIDINE CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2008-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035893-A1 | TRIAZOLOPYRIDINE CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | FLT3, QDPR, CYP1A2 | MGLL 3483/4885FAAH 707/4885GPX4 1580/4885 |
| US-20110071161-A1 | TRIAZOLOPYRIDINE CARBOXAMIDE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | FLT3, QDPR, CYP1A2 | MGLL 3483/4885FAAH 707/4885GPX4 1580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.